CNTX

Rating neutralAI Memo

Context Therapeutics

As of 2026-05-20/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-20 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

CTIM-76 Phase 1a interim data expected in June 2026 • 2026-06-30

Expected move: -5%

Biggest risk

The bear case is that this remains a thinly covered, early-stage biotech with binary clinical risk, no analyst revision signal in the packet, loose peer support, and continuing financing/dilution overhang. Any delay, weak efficacy signal, or safety issue in CTIM-76 would likely compress the multiple quickly.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Bullish interpretation centers on the June 2026 CTIM-76 interim data readout, with additional support from CT-202 moving toward first-patient dosing in Q3 2026 and cash runway into mid-2027. If the data are clean and the platform starts to look clinically differentiated, the stock could rerate sharply from a low base.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-20

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway into mid-2027, but financing remains a standing overhang
Bullish interpretation centers on the June 2026 CTIM-76 interim data readout, with additional support from CT-202 moving toward first-patient dosing in Q3 2026 and cash runway into mid-2027.
If the data are clean and the platform starts to look clinically differentiated, the stock could rerate sharply from a low base.

BearKey bullets

CT-202 first-patient dosing could slip beyond the Q3 2026 target, reinforcing execution concerns.
CTIM-76 Phase 1a data could disappoint on efficacy, safety, or durability and reset the thesis.
Low coverage and loose peer comparability mean there is limited external validation for valuation, analyst revisions, or mechanism-level read-through.

WatchKey bullets

CTIM-76 Phase 1a interim data expected in June 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=55%)

Bull/Bear spread: +133% / -57%

Vs latest close: Bull +133% · Base -5% · Bear -57%

Scenario probabilities

Bull Target: $6 (p=20%)Base Target: $2 (p=55%)Bear Target: $1 (p=25%)

Commentary

This remains a cautious monitoring name. The strongest evidence is still the company’s own SEC filing trail, which points to June 2026 CTIM-76 interim data, Q3 2026 CT-202 first-patient dosing, and runway into mid-2027 [#10-Q-2026-05-06]. Coverage is low, the packet contains no useful analyst revision or target-change signal, social context is empty, and available peer candidates are only loose same-sector small-cap biotech checks rather than direct therapeutic comps. Conviction should therefore stay modest and tied to the upcoming clinical readout rather than to any broad thesis expansion.

As of 2026-05-20 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway into mid-2027, but financing remains a standing overhang

Scenarios

Bull Target (Scenario probability)

$6 / p=20% prob

Base Target (Scenario probability)

$2 / p=55% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Price $2 as of 2026-06-02

Nearest Scenario: Base (∆ 5%)

Targets vs latest close: Bull +133% · Base -5% · Bear -57%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-30
CTIM-76 Phase 1a interim data expected in June 2026
The latest 10-Q says Context dosed the first patient in the CTIM-76 Phase 1 trial in January 2025, received FDA Fast Track designation for platinum-resistant ovarian cancer on April 2, 2026, and expects to share Phase 1a interim data in June 2026. This is the clearest near-term binary catalyst and the main potential thesis driver [#10-Q-2026-05-06].
Prob 70.00% • Move 38.00% • Priced-in 45.00%
EVENT2026-09-30
CT-202 first-patient dosing targeted for Q3 2026
The 10-Q states that Context submitted CT-202 to the Australian Bellberry Human Research Ethics Committee in March 2026 and expects to dose the first patient in the Phase 1 trial in the third quarter of 2026. Hitting that timing would support the multi-asset platform story; delay would reinforce execution skepticism [#10-Q-2026-05-06].
Prob 62.00% • Move 22.00% • Priced-in 32.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Runway into mid-2027, but financing remains a standing overhang
2027-06-30
The 10-Q says existing cash is expected to fund the Phase 1a dose-escalation portions of CTIM-76 and CT-95, CT-202 trial initiation, and operations into mid-2027, while also warning that substantial additional capital will be needed. That keeps dilution terms and financing access central to the equity case [#10-Q-2026-05-06].
Prob 74% • Move 16% • Priced-in 58%

Risks

CT-202 first-patient dosing could slip beyond the Q3 2026 target, reinforcing execution concerns.
CTIM-76 Phase 1a data could disappoint on efficacy, safety, or durability and reset the thesis.
Low coverage and loose peer comparability mean there is limited external validation for valuation, analyst revisions, or mechanism-level read-through.
The company says substantial additional capital will be needed, so dilution risk remains high even with runway into mid-2027.

Peers

Symbol	Summary
CRBP	Same-sector small-cap biotech comparator from the packet; useful for broad clinical-stage risk appetite and event-volatility framing, but not a direct mechanism, indication, or asset-stage comp for CNTX.
ELTX	Same-sector small-cap biotech comparator from the packet; useful mainly for financing-risk and development-stage sentiment context, with limited direct therapeutic comparability.
FATE	Same-sector small-cap biotech comparator from the packet; relevant as a higher-profile clinical-stage risk-appetite check, but still too loose to support valuation or clinical read-through confidence.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-20

AI Stock Memo: CNTX - Context Therapeutics - RankAlpha